Scholars Central

Conference abstractPublished 18 Aug 2016

Repurposed therapies in AML and MDS

Authors: Ken Mills

Queen’s University Belfast, UK

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

There is an urgent and unmet need for new effective and less toxic therapies for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) patients. This is particularly important for the elderly patients who are often unfit for intensive therapies. The number of mutations that have now been reported as being associated with both AML and MDS mean the potential mutation combinations would mean a plethora of drugs may be required. The number of new therapies being developed through the drug pipeline of pre-clinical, phase 1, 2 and 4 before FDA approval is very low and can take up to 15-18 years and billions of dollars. However, there are a large range of approved therapies for all types of conditions such as diabetes, epilepsy, cardiac diseases, mental disorders etc., which are known to the safe and well tolerated in humans. The question is could any of these therapies be repurposed or repositioned to be a treatment for AML or MDS and if so how can the most effective be identified? We have employed alternative approaches to identify candidate drugs for repurposing and these approaches and the results will be discussed in context of AML and MDS.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • BylineArticles whose byline prints “Ken Mills”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels